These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21575312)

  • 41. Clinical trial research in focus: overcoming barriers in MDR-TB clinical trials.
    Zumla A; Abubakar I
    Lancet Respir Med; 2017 Apr; 5(4):247-248. PubMed ID: 28353422
    [No Abstract]   [Full Text] [Related]  

  • 42. Community-based management of multidrug-resistant tuberculosis in South Africa.
    Bekker LG; Wood R
    Int J Tuberc Lung Dis; 2010 Apr; 14(4):379. PubMed ID: 20202291
    [No Abstract]   [Full Text] [Related]  

  • 43. Getting health services to three million people with TB.
    Pérez H
    J Int AIDS Soc; 2014; 17(1):19079. PubMed ID: 24666595
    [No Abstract]   [Full Text] [Related]  

  • 44. Programmatic management of multidrug resistant TB.
    Sarin R
    Indian J Tuberc; 2009 Oct; 56(4):171-3. PubMed ID: 20469727
    [No Abstract]   [Full Text] [Related]  

  • 45. Optimizing MDR-TB clinical trials: insights from the first global MDR-TB Clinical Trials Landscape Meeting.
    Horsburgh CR; Rusen ID; Mitnick CD
    Int J Tuberc Lung Dis; 2016 Dec; 20(12):1-3. PubMed ID: 28240564
    [No Abstract]   [Full Text] [Related]  

  • 46. MDR tuberculosis challenges global health-care targets.
    The Lancet Respiratory Medicine
    Lancet Respir Med; 2013 Dec; 1(10):755. PubMed ID: 24461743
    [No Abstract]   [Full Text] [Related]  

  • 47. Will molecular diagnosis of drug-resistant tuberculosis improve patient outcomes?
    Jonsson G; Furin J
    Int J Tuberc Lung Dis; 2012 Jan; 16(1):4-5. PubMed ID: 22236840
    [No Abstract]   [Full Text] [Related]  

  • 48. Access to new drugs and the global drug-resistant TB crisis: a case series from KwaZulu-Natal, South Africa.
    Master I; Furin J
    Int J Tuberc Lung Dis; 2016 Jul; 20(7):985-7. PubMed ID: 27287655
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Control of tuberculosis in India.
    Mohapatra PR
    Lancet; 2003 Oct; 362(9391):1243. PubMed ID: 14568763
    [No Abstract]   [Full Text] [Related]  

  • 50. Estonia races to halt multidrug-resistant TB before HIV takes hold.
    Lindsay M
    Bull World Health Organ; 2002; 80(6):519. PubMed ID: 12132016
    [No Abstract]   [Full Text] [Related]  

  • 51. Responding to the multidrug-resistant tuberculosis crisis: mainstreaming programmatic management to the Philippine National Tuberculosis Programme.
    Quelapio MI; Mira NR; Orillaza-Chi RB; Belen V; Muñez N; Belchez R; Egos GE; Evangelista M; Vianzon R; Tupasi TE
    Int J Tuberc Lung Dis; 2010 Jun; 14(6):751-7. PubMed ID: 20487615
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Curing multidrug-resistant tuberculosis: not all about the money.
    Gruber K
    Lancet Respir Med; 2016 Nov; 4(11):870-871. PubMed ID: 27799128
    [No Abstract]   [Full Text] [Related]  

  • 53. Multidrug-resistant TB in Zambia: review of national data from 2000 to 2011.
    Kapata N; Chanda-Kapata P; Bates M; Mwaba P; Cobelens F; Grobusch MP; Zumla A
    Trop Med Int Health; 2013 Nov; 18(11):1386-91. PubMed ID: 24033538
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
    Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
    Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multidrug-resistant tuberculosis: standardized or individualized treatment? The question has already been answered.
    Laniado-Laborín R
    Expert Rev Respir Med; 2010 Apr; 4(2):143-6. PubMed ID: 20406077
    [No Abstract]   [Full Text] [Related]  

  • 56. Modeling the impact of bedaquiline treatment strategies on the multidrug-resistant tuberculosis burden in India.
    Mehra M; Kambili C; Potluri R; Rhines A; Singh V; Thomas A
    Int J Tuberc Lung Dis; 2017 Aug; 21(8):902-909. PubMed ID: 28786799
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multidrug-resistant tuberculosis on Australia's northern border.
    Simpson G
    Intern Med J; 2011 Nov; 41(11):759-61. PubMed ID: 22077943
    [No Abstract]   [Full Text] [Related]  

  • 58. Six-Month Response to Delamanid Treatment in MDR TB Patients.
    Hewison C; Ferlazzo G; Avaliani Z; Hayrapetyan A; Jonckheere S; Khaidarkhanova Z; Mohr E; Sinha A; Skrahina A; Vambe D; Vasilyeva I; Lachenal N; Varaine F
    Emerg Infect Dis; 2017 Oct; 23(10):1746-8. PubMed ID: 28767036
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictor of multidrug resistant tuberculosis in southwestern part of Ethiopia: a case control study.
    Gobena D; Ameya G; Haile K; Abreha G; Worku Y; Debela T
    Ann Clin Microbiol Antimicrob; 2018 Jul; 17(1):30. PubMed ID: 29970076
    [TBL] [Abstract][Full Text] [Related]  

  • 60. India plans to expand access to new tuberculosis drug.
    Sharma DC
    Lancet; 2017 Feb; 389(10070):685. PubMed ID: 28229866
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.